Gemini Therapeutics (NASDAQ:GMTX) Reaches New 52-Week High at $70.27

Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTXGet Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $70.27 and last traded at $70.08, with a volume of 149624 shares trading hands. The stock had previously closed at $67.50.

Gemini Therapeutics Price Performance

The firm has a fifty day moving average of $59.32 and a two-hundred day moving average of $52.91. The stock has a market capitalization of $3.04 billion, a P/E ratio of -1.35 and a beta of -0.12.

Hedge Funds Weigh In On Gemini Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GMTX. Virtu Financial LLC purchased a new position in Gemini Therapeutics in the second quarter valued at about $35,000. Goldman Sachs Group Inc. grew its stake in shares of Gemini Therapeutics by 80.1% during the second quarter. Goldman Sachs Group Inc. now owns 36,635 shares of the company’s stock worth $62,000 after acquiring an additional 16,297 shares during the last quarter. UBS Group AG purchased a new stake in shares of Gemini Therapeutics during the second quarter worth about $234,000. Bank of Montreal Can purchased a new stake in shares of Gemini Therapeutics during the second quarter worth about $276,000. Finally, Renaissance Technologies LLC grew its stake in shares of Gemini Therapeutics by 2,850.4% during the first quarter. Renaissance Technologies LLC now owns 351,100 shares of the company’s stock worth $488,000 after acquiring an additional 339,200 shares during the last quarter. Hedge funds and other institutional investors own 75.42% of the company’s stock.

Gemini Therapeutics Company Profile

(Get Free Report)

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.

See Also

Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.